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155-61.MMENTARYAtrial thrombosis in advanced mitral stenosis with atrial fibrillation:
What should we expect?Carlos-A. Mestres, MD, PhD, FETCSIn this issue of the Journal of Thoracic and Cardiovascular
Surgery, Luo and colleagues1 publish their study intended to
evaluate the role of left atrial endocardial dysfunction and
platelet activation in left atrial thrombosis (LAT). Their
study included 80 patients with rheumatic mitral stenosis(MS) and atrial fibrillation (AF) with (40 patients) or
without (40 patients) LAT. They also evaluated the blood
of 15 apparently healthy volunteers and 10 specimens of
left atrial appendages harvested from donor hearts, looking
at the expressions as well as plasma concentrations of von
Willebrand factor (vWF) and P-selectin protein. Patients
with LAT had bigger left atrial dimensions and smaller
valve orifices. Luo and colleagues1 found no differences
in plasma levels of vWF and P-selectin between the left
atrium and peripheral blood. They concluded that the over-
expression of the vWF gene in the left atrial appendage may
contribute to the increase in plasma vWF levels. What is ex-
tracted from this contribution is that vWF and P-selectin are
supposed to play a collaborative role in thrombosis on the
injured endothelium in left atrial appendage.
Rheumatic MS as a sequela of acute rheumatic fever is a
still common disease in various parts of the world,2 and
because it is a chronic inflammatory disease, a number of
complex phenomena are observed. Subclinical chronic car-




Dassociates3 in an elegant study in which 50 samples from the
left atrium retrieved at the time of closed mitral commissur-
otomy demonstrated inflammatory infiltrates and confirmed
the predominant presence of T cells. That study improved
the understanding of chronic inflammation in this setting.
Some aspects of this contribution1 should be highlighted.
There were differences between left atrial diameter and
mitral valve orifice area in patients with MS and LAT and
those in patients without LATand control subjects. Although
it is not surprising that the left atrial diameter was larger and
the mitral valve orifice area smaller in patients with LAT,
this finding and associated AF represent very advanced dis-
ease. Histologic examination showed the endocardium to be
fibrous in patients with AF and showed LAT to be associated
with chronic endocardial scarring.
Furthermore, peripheral plasma levels of vWF and
P-selectin were higher in patients with MS and LAT than
in patients without LAT and obviously in control subjects,
but the samewas not true in the LA appendage. Gene expres-
sion of P-selectin in LA appendage was not different among
groups. vWF influences platelet adhesion onto endocardial
collagen. P-selectin is amarker of platelet activation because
of its translocation from the platelet granules to the platelet
surface when the granules are secreted,4 suggesting then
that patients with MS have an increased platelet activation
that might be more intense in the patients with LAT. Platelet
activation is a very complex phenomenon, and it is related to
a variety of triggers.5 This study partially addresses this
issue. Luo and colleagues’ findings1 may explain some of
the chronic changes seen in patients with MS with and
without LAT. In patients with MS and AF, the development
of LAT is a step forward in the disease, which is also related
to disturbances in hemodynamics. The smaller the valve
orifice area, themore turbulent the intra-atrial flow, including
the left atrial appendage where thrombi originate. As Luo
and colleagues1 confirmed, chronic endothelial scar seen
on histologic studies and other factors including collagen
may play a role in activating platelets.5 The biochemical re-
sults of this investigation are consistentwith an advanced dis-
ease that is represented by AF and LAT, with the latter being
the ultimate evolution of intra-atrial turbulent flow andThe Journal of Thoracic and Carendocardial remodeling. An injured endothelium such as
found inMS with AF may lead to modifications in the endo-
crine and paracrine functions.
This contribution is, of course, of scientific interest,
although there are some concerns about practicality.
The findings suggest a combination of effects of vWF and
P-selectin that contribute to thrombosis on an injured
myocardium. This may raise questions about eventual mod-
ifications of antithrombotic therapy in patients with MS and
AF and whether such a therapy might eventually prevent
LAT. It is probably too early for Luo and colleagues to
give an answer, and their suggestion that stronger antiplatelet
therapy could be beneficial should not be taken lightly. Stron-
ger antiplatelet therapy is a must and may not match the ef-
fect of dual antiplatelet therapy. Other clinical studies
have suggested that single antiplatelet therapy and not anti-
coagulation may be effective in preventing thrombotic
events on rough surfaces, such as prosthetic valve rings
immediately after valve replacement.6 The chronically
scarredmyocardiumas shown in this study is a good example
of a rough surface that needs pharmacologic intervention.
Further investigations on the complex topicof platelet activa-
tion and thrombosis in the setting of MS are warranted.References
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